固本益肠片联合复方谷氨酰胺和曲美布汀治疗肠易激综合征的临床研究

目的探讨固本益肠片联合复方谷氨酰胺和曲美布汀治疗肠易激综合征的临床疗效。方法收集2014年3月—2016年3月在上海市同仁医院接受治疗的肠易激综合征患者86例,随机分为对照组(43例)和治疗组(43例)。对照组口服复方谷氨酰胺颗粒,1袋/次,3次/d,同时口服马来酸曲美布汀片,0.1 g/次,3次/d。治疗组在对照组的基础上口服固本益肠片,4片/次,3次/d。两组患者均连续治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者肠道症状尺度表(BSS)评分、血浆生长抑素(SS)、血管活性肠肽(VIP)及胃动素(MTL)水平变化。结果治疗后,对照组和治疗组总有效率分别为81.14%和95.35%,两组总有效率比较差异具有统计学意义(P0.05)。治疗后,两组患者BBS总积分明显低于同组治疗前,同组治疗前后比较差异有统计学意义(P0.05);且与对照组治疗后相比,治疗组降低的更明显,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者血浆SS、VIP和MTL水平均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者比对照组降低的更明显,两组比较差异具有统计学意义(P0.05)。结论固本益肠片联合复方谷氨酰胺和曲美布汀治疗肠易激综合征效果显著,可明显改善患者临床症状及生活质量,具有一定的临床推广应用价值。

Clinical study on Guben Yichang Tablets combined with compound glutamine and trimebutine in treatment of irritable bowel syndrome

Objective To investigate the clinical efficacy of Guben Yichang Tablets combined with compound glutamine and trimebutine in treatment of irritable bowel syndrome. Methods Patients (86 cases) with irritable bowel syndrome in Shanghai Tongren Hospital from March 2014 to March 2016 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in control group were po administered with Compound Glutamine Granules, 1 bag/time, three times daily. And patients in control group were also po administered with Trimebutine Maleate Tablets, 0.1 g/time, three times daily. Patients in treatment group were po administered with Guben Yichang Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the BSS scores, SS, VIP, and MTL levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in control and treatment groups were 81.14% and 95.35%, respectively, and there were differences between two groups (P<0.05). After treatment, the BBS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the BBS score in treatment group decreased more significantly than that in control group, with significant difference between two groups (P<0.05). After treatment, SS, VIP, and MTL levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). These indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Guben Yichang Tablets combined with compound glutamine and trimebutine have a significant clinical efficacy in treatment of irritable bowel syndrome, and can significantly improve the clinical symptoms and quality of life, which has a certain clinical application value.